For the other CV outcomes, SGLT2 inhibitor contributed to risk reductions of MACE (RR 0.92, 95% CI 0.88–0.99, P = .03, I2 = 0%) and myocardial infarction (RR 0.89, 95% CI 0.80–0.99, P = .03, I2 = 0%) in patients without HF. The gene discussed is SLC5A2; the disease is myocardial infarction.